Use of concentrated insulin human regular (U-500) for patients with diabetes
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: The efficacy and safety of and key clinical considerations for using U-500 insulin human regular in the treatment of high-dose insulin-treated patients in a wide variety of settings are examined. SUMMARY: U-500 regular insulin has been available in the United States since 1952, but only recently has it become more commonly prescribed for patients requiring large amounts of insulin to improve their blood glucose control. This use coincides with the increasing rates of obesity and type 2 diabetes associated with significant insulin resistance, which can necessitate the need for doses of insulin exceeding 200 units/day. However, many health care professionals are relatively unfamiliar with this concentrated insulin formulation. U-500 regular insulin has a pharmacokinetic and pharmacodynamic profile that differs from U-100 human insulins and analogues. Although no randomized clinical trials using U-500 insulin have been performed, eight case series (involving 160 patients) have been published. Rare or infrequent occurrences of hypoglycemia with U-500 insulin have been reported. Of the medication errors associated with U-500 insulin, administration and dispensing errors occurred most frequently. With the increase in prescribing of U-500 insulin, pharmacists must be aware of the complex issues involved with appropriate prescribing, dispensing, and provision of patient education to maximize patient safety and avoid administration errors and dosing confusion. CONCLUSION: U-500 insulin is efficacious and safe for patients with type 2 diabetes who require a high dosage of insulin to control hyperglycemia. However, health care professionals should be well educated and vigilant about patient safety issues regarding the drug's prescription, dosing, and administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · cited 2×
“Approximately one third of the patients treated with U-500 insulin were also receiving concomitant oral antihyperglycemic medications, predominantly metformin, consistent with current treatment guidelines.(13) It is important to note that such combination therapy is not approved by the Food and Drug Administration (FD…”
BackgroundStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984) · Diabetes Care · doi:10.2337/diacare.7.2.188 · Cited by 341
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
Musso, C., Cochran, E., Moran, S. A., Skarulis, M. C., Oral, E. A., Taylor, S., & Gorden, P. (2004) · Medicine · doi:10.1097/01.md.0000133625.73570.54 · Cited by 264
Galloway, J. A., Spradlin, C. T., Nelson, R. L., Wentworth, S. M., Davidson, J. A., & Swarner, J. L. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.366 · Cited by 226
ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002) · Medicine · doi:10.1097/00005792-200203000-00001 · Cited by 223
Musso, C., Cochran, E., Javor, E., Young, J., DePaoli, A. M., & Gorden, P. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.021 · Cited by 146
Cited by
de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125
“Currently, U-500R must be delivered either by U-100 insulin syringes with unit markings that represent one-fifth of the actual U-500R dose administered or by tuberculin syringes with markings showing volume in milliliters (3,5,24,25).”
BackgroundSelf-citationClinical use of U-500 regular insulin: Review and meta-analysis
Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600229 · Cited by 94
Halpern, R., Iqbal, S. U., Kazis, L. E., Macarios, D., & Badamgarav, E. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.1.25 · Cited by 94
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
Self-citation
Metadata
- Authors
- Segal, A. R., Brunner, J. E., Burch, F. T., & Jackson, J. A.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-15
- Volume
- 67
- Issue
- 18
- Pages
- 1526-1535
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2168212414
- Cited by
- 60
- References
- 9
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.